** Shares of Emergent BioSolutions EBS.N rise 20.1% to $11.05 premarket
** Late on Wednesday, drugmaker raised the lower end of its annual rev. forecast to $1.07 bln from $1.05, while keeping upper end at $1.13 bln
** It also expects a narrower loss of $30 mln to $50 mln for 2024 versus its earlier estimate of $75 mln to $115 mln
** Co's Q3 adj. EPS of $1.37 beat Wall Street estimates of 14 cents - LSEG
** However, EBS' Q3 rev. of $293.8 mln missed estimates of $297.5 mln
** Co also said its smallpox drug Tembexa was included in a clinical trial for mpox led by the Africa Centres for Disease Control and Prevention
** Up to last close, stock has almost quadrupled YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.